Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6 USD | +3.27% | -7.83% | -26.98% |
May. 30 | Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target | MT |
May. 13 | Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 467.2 | 31.57 | 21 | 29.86 | 21.15 | - | - |
Enterprise Value (EV) 1 | 408.4 | 31.57 | 21 | 29.86 | 21.15 | 21.15 | 21.15 |
P/E ratio | -5.76 x | -1.38 x | -1.25 x | - | - | - | - |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 12,831 | 14,754 | 21,000 | 36,335 | 36,395 | - | - |
Reference price 2 | 36.41 | 2.140 | 1.000 | 0.8217 | 0.5810 | 0.5810 | 0.5810 |
Announcement Date | 3/16/21 | 3/31/22 | 3/31/23 | 3/18/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | - | -46.28 | - | - | - | -33.85 | -40.72 | -55.37 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | -46.49 | - | - | - | - | - | - |
Net income | -4.069 | -46.49 | -21.71 | -13.88 | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - |
EPS | -0.4100 | -6.320 | -1.550 | -0.8000 | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/25/20 | 3/16/21 | 3/31/22 | 3/31/23 | 3/18/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | - | - | - | - | - | -7.804 | -8.182 | -8.708 | -9.157 | -9.83 | -10.05 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - |
Net income | -3.035 | - | -8.896 | - | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - |
EPS | -0.2100 | - | -0.4200 | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 8/15/22 | 11/14/22 | 8/14/23 | 11/13/23 | 3/18/24 | 5/13/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | 58.8 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 3/25/20 | 3/16/21 | 3/31/22 | 3/31/23 | 3/18/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.14% | 21.15M | |
+15.51% | 121B | |
+13.70% | 107B | |
-4.86% | 24.82B | |
+1.63% | 22.48B | |
-9.84% | 18.32B | |
-42.28% | 16.33B | |
-15.74% | 15.31B | |
+3.88% | 14.08B | |
+25.15% | 11.74B |
- Stock Market
- Equities
- FBRX Stock
- Financials Forte Biosciences, Inc.